Methods of treating uveal melanoma with a pkc inhibitor
AssigneeIdeaya Biosciences, Inc.
InventorsMATTHEW ANTHONY MAURER, MICHAEL GABRIEL O'QUIGLEY, JULIE HAMBLETON
Life of this patent
Estimating the term…
Abstract
Provided herein is a neoadjuvant therapy and/or adjuvant therapy for the treatment of uveal melanoma, inter alia, ocular tumors in uveal melanoma to reduce the incidence of metastasis and/or enucleation and/or preserving eye function.
Claims43
A method of treating uveal melanoma in a patient having an ocular tumor, the method comprising
- a) administering a PKC inhibitor to the patient as a neoadjuvant therapy;
- b) reducing the size of the ocular tumor by at least 10%;
- and
- c) treating the reduced-size ocular tumor with an interventional procedure.
A method of treating a patient having uveal melanoma with an ocular tumor with a size indicated for an interventional procedure comprising enucleation of the eye, the method comprising
- a) administering a PKC inhibitor to the patient as a neoadjuvant therapy;
- b) reducing the size of the ocular tumor by at least 10%;
- and
- c) treating the reduced-size ocular tumor with an interventional procedure other than enucleation.
A method of treating a patient having uveal melanoma with an ocular tumor with a size indicated for an interventional procedure comprising irradiating the ocular tumor, the method comprising
- a) administering a PKC inhibitor to the patient as a neoadjuvant therapy;
- b) reducing the size of the ocular tumor by at least 10%;
- and
- c) treating the reduced-size ocular tumor with an interventional procedure other than enucleation.
A method of treating uveal melanoma in a patient having an ocular tumor, the method comprising:
- a) determining a first therapeutically effective dose of radiation for treating the ocular tumor;
- b) administering a PKC inhibitor to the patient as a neoadjuvant therapy;
- c) reducing the size of the ocular tumor;
- and
- d) irradiating the reduced-size ocular tumor with a second therapeutically effective dose of radiation less than the first therapeutically effective dose of radiation.
Dependencies are inferred from the claim text.